|Articles|October 13, 2015

OmniComm Infographic eSource Easier Than You Think

External Link - Advanstar ACT Omni eSource[jess]10-6-15.pdf

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Pharmaceutical Executive Daily: Kardigan Sets Terms for $350 Million IPO

ByNicholas Jacobus

June 12th 2026

Zepzelca Fails to Meet Main Goal of ‌Phase III Lagoon Trial in Second-Line Small Cell Lung Cancer

ByNicholas Jacobus

June 12th 2026

Rick Winningham: Building Leaders Behind the Pipeline

ByNicholas Jacobus

Published: June 12th 2026 | Updated: June 12th 2026

Kardigan Planning for $350 Million IPO Raise: Report

ByNicholas Jacobus

June 12th 2026

The Future for Disease Modifying Therapies for Lysosomal Disorders

ByMike Hollan,Lisa Bollinger

June 12th 2026

OmniComm Infographic eSource Easier Than You Think

Related Content

Pharmaceutical Executive Daily: Kardigan Sets Terms for $350 Million IPO

Zepzelca Fails to Meet Main Goal of ‌Phase III Lagoon Trial in Second-Line Small Cell Lung Cancer

Rick Winningham: Building Leaders Behind the Pipeline

Kardigan Planning for $350 Million IPO Raise: Report

The Future for Disease Modifying Therapies for Lysosomal Disorders

Trending on PharmExec

How New Technologies Are Impacting the Vaccine Market

Pharmaceutical Executive Daily: Kardigan Sets Terms for $350 Million IPO

Kardigan Planning for $350 Million IPO Raise: Report

Zepzelca Fails to Meet Main Goal of ‌Phase III Lagoon Trial in Second-Line Small Cell Lung Cancer

Deepening Ties: Why China is Becoming Big Pharma's Most Essential R&D Partner